GSK told to pay higher royalties to AZ on Zejula sales

A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ovarian cancer drug Zejula, which competes with AZ’s top-selling PARP inhibito

J&J gets restricted label for PARP drug Akeega in EU

Johnson & Johnson’s entry into the PARP inhibitor market with prostate cancer therapy Akeega has started with a disappointing ruling in the EU.

Lynparza under siege in first-line prostate cancer

Battle lines are being drawn up in metastatic castration-resistant prostate cancer (mCRPC), with AstraZeneca and Merck & Co’s market-leading PARP inhibitor Lynparza fi

GSK hits another oncology hurdle as Zejula use is limited ag...

GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patient

GSK starts 2020 on a high, but warns of tougher times ahead

GSK takes fight to AZ/Merck & Co with first-line ovarian can...

The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class